DSM-Firmenich

DSM-Firmenich is expanding its presence in Indonesia: the new Jakarta office brings together the teams for Taste, Texture & Health, Perfumery & Beauty and Health, Nutrition & Care. At the same time, the production site in Karawang was expanded with drying equipment and additional blending capacity for culinary products. The plant runs entirely on renewable electricity; electric heating systems are expected to reduce CO2 emissions by around 300 tonnes per year, and heat recovery should cut energy consumption by about 16 percent. The company has been active in Indonesia for more than 35 years, which is considered one of the most important markets in Southeast Asia. » Mere på finanzen.net

DSM-Firmenich has agreed a partnership with AI start-up Boltz to integrate Boltz’s proprietary base models into the discovery of new ingredients. The AI models will be combined with DSM-Firmenich’s database of taste and smell receptors to predict and design molecular structures. The aim is a deeper understanding of interactions between molecules and specialized proteins to develop new fragrance and flavor molecules. » Mere på finanzen.net

Inge Massen-Biemans will assume the role of chief sustainability officer at DSM-Firmenich on 1 November 2026, succeeding Katharina Stenholm, who will leave the company at the end of 2026. Massen-Biemans has been with the company for 25 years, is currently vice president Nutrition, Health & Social Impact, and previously worked in Corporate & Public Affairs. She will remain country head for the Netherlands and, as CSO, will report directly to CEO Dimitri de Vreeze. » Mere på finanzen.net

DSM-Firmenich has filed a patent infringement lawsuit at the Xiong'an New District court in Hebei against several Chinese companies and a research institute. The case centers on the unauthorized use of a patent to produce sclareol, a precursor for amber fragrances; DSM-Firmenich is seeking an injunction and damages. The announcement had only a minor impact on the share price. » Mere på finanzen.net

Thomas Leysen is stepping down as chairman of DSM-Firmenich’s board; the company proposes Richard Ridinger for election by shareholders at the extraordinary general meeting on 19 October 2026. Leysen will remain chairman until the vote and cites the completed integration after the merger and a desire to have more time for other mandates as reasons for his resignation. Ridinger has been a board member at DSM-Firmenich since 2023, previously worked at Firmenich, and is the former CEO of Lonza as well as former chairman of Brenntag and Recipharm. » Mere på finanzen.net